Hansen, Morten1; Sonne, David Peick2; Mikkelsen, Kristian Hallundbæk3; Gluud, Lise Lotte4; Vilsbøll, Tina5; Knop, Filip Krag5
1 Department of Haematology, Herlev and Gentofte Hospital, The Capital Region of Denmark2 Internal Medicine, Gentofte, Herlev and Gentofte Hospital, The Capital Region of Denmark3 Medicinsk Afdeling F og Akutklinik4 Gastrounit, Medical Division, Gastrounit, Amager and Hvidovre Hospital, The Capital Region of Denmark5 Center for Diabetesforskning, Internal Medicine, Gentofte, Herlev and Gentofte Hospital, The Capital Region of Denmark
protocol for a systematic review with meta-analysis of randomised controlled trials
In addition to the lipid-lowering effect of bile acid sequestrants (BASs), they also lower blood glucose and, therefore, could be beneficial in the treatment of patients with type 2 diabetes mellitus (T2DM). Three oral BASs are approved by the US Food and Drug Administration (FDA) for the treatment of hypercholesterolaemia: colestipol, cholestyramine and colesevelam. The BAS colestimide/colestilan is used in Japan. Colesevelam was recently approved by the FDA for the treatment of T2DM. We plan to provide a systematic review with meta-analysis of the glucose-lowering effect of BASs with the aim to evaluate their potential as glucose-lowering agents in patients with T2DM.